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Abstract
Introduction and hypothesis The Patient Global Impression of
Improvement (PGI-I) and International Consultation of
Incontinence Questionnaire – Short Form (ICIQ-SF) are val-
idated instruments for the assessment of patient reported out-
come measures (PROM) following treatment of stress urinary
incontinence (SUI). However, there is a paucity of evidence as
to what represents a successful postintervention ICIQ-SF
score. To determine the correlation between the postoperative
ICIQ-SF scores with the PGI-I outcomes, the latter was con-
sidered one of the standard PROM following surgical treat-
ment for SUI. The aim of this study was to determine, and if
appropriate validate, an ICIQ-SF cut-off score that can predict
a successful PROM as determined by PGI-I.
Methods Four large datasets yielding 674 ICIQ-SF score/PGI-I
outcome data pairs were used in this study for (a) determining
and (b) validating the cut-off ICIQ-SF score for a successful
PGI-I outcome. Two long-term follow-up datasets were used
representing follow-up periods of 3 and 8 years of a random-
ized controlled trial (RCT) performed between April 2005 and
April 2007 in a tertiary urogynaecology centre in Scotland,
UK. All patients had urodynamic SUI or mixed urinary incon-
tinence (MUI, with predominant SUI) and were randomized to
treatment with either an inside-out or an outside-in
transobturator tape (TVT-O or TOT, respectively) as a sole
procedure. The datasets yielded 432 ICIQ-SF score/PGI-I out-
come data pairs. Successful outcome was defined as Bvery
much improved/much improved^ on the PGI-I scale. SPSS v.
22.0 (IBM Corp., Armonk, NY) was used for all statistical
analyses. The correlations and cut-off scores generated were
then validated on two independent datasets representing the
1-year and 4-year follow-up periods of the multicentre RCT
in six units in the UK. The datasets yielded 242 ICIQ-SF
score/PGI-I outcome data pairs. All patients had urodynamic
SUI or MUI (with predominant SUI) and were randomized to
either adjustable single incision minisling (SIMS) or TVT-O.
Results Significant correlations at the 0.01 level (two-tailed)
were clearly demonstrated between ICIQ-SF scores at follow
up and PGI-I outcomes in terms of success/failure in both the
generation and validation datasets. Higher ICIQ-SF scores cor-
related with a ‘poorer’ PGI-I score. Using ROC analysis, a
postoperative ICIQ-SF score of 6 was validated as approxi-
mately 90% sensitive and 85% specific for success/failure with
a high Cohen’s kappa coefficient of 0.83 (95 %CI 0.74 – 0.89).
Conclusions This two-stage study provided a robust well-
validated postoperative ICIQ-SF cut-off score (of 6/21) that is
likely to be associatedwith a patient-reported successful outcome
on the PGI-I following surgical treatment with a midurethral
sling in women at different stages of follow-up over 1 – 8 years.
Such a cut-off score could enable the comparison of results be-
tween various studies and serve as a valuable guide for surgeons
to counsel patients before and/or after surgical treatment. Our
study fills a research gap in providing a way to compare trial
results when baseline ICIQ-SF scores are not available.
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Introduction
Urinary incontinence (UI) is a distressing condition that neg-
atively affects women’s quality of life (QoL). Therefore, as-
sessment and evaluation of patients’ symptom severity and
QoL prior to and after an intervention are essential [1, 2]. A
number of self-assessment questionnaires have been recom-
mended [3, 4], but simplicity and brevity are important fea-
tures in designing patient self-assessment questionnaires [3,
4]. The International Consultation of Incontinence
Questionnaire – Short Form (ICIQ-SF) is a validated subjec-
tive measure of severity and impact of UI on the QoL in
women [1]. The ICIQ-SF is formed of six items of which four
main items ask for rating of UI symptoms in the past 4 weeks.
The scores for items 3, 4 and 5 are taken for the final ICIQ-SF
score. Items 1 and 2 are demographic and the final item is a
self-diagnostic item for the type of UI. The Patient Global
Impression of Improvement (PGI-I) is a seven-point scale in-
strument of patient reported outcome measures (PROM)
which is validated to assess PROM following treatment of
stress UI (SUI) [2]. However, there is a paucity of evidence
as to what represents a successful postintervention ICIQ-SF
score, and this is further complicated when the baseline score
is not available [5]. There is a significant drive to conduct and
compare the long-term follow-up results of randomized con-
trolled trials (RCTs) related to UI interventions; however,
some of these RCTs do not have baseline ICIQ-SF scores
simply because the ICIQ-SF was developed only in 2004.
The objective of this study was to determine the correlation
between the postoperative ICIQ-SF scores and the PGI-I out-
come. The latter is considered the standard PROM following
surgical treatment for SUI. If we did indeed find a significant
correlation, we intended to determine, and if appropriate val-
idate, a postoperative ICIQ-SF cut-off score that could predict
a successful PROM as determined by PGI-I. Such a score
would facilitate the comparison of results among clinical trials
using different tools to asses PROM and especially those in
which long-term follow-up is feasible. Such a score could also
be a valuable aid in the counselling of patients and facilitating
their postoperative follow-up.
Materials and methods
Two PROM assessment tools were assessed: ICIQ-SF and
PGI-I. ICIQ-SF has a maximum score of 21; the higher the
score, the more severe is the UI, but there is no normal score
(Appendix 1). The PGI-I is a seven-point transition scale that
comprises a single question asking patients to rate their uri-
nary tract condition now as compared with how it was before
treatment on a scale from 1 (very much better) to 7 (very much
worse). Outcomes of Bmuch improved^ or Bvery much im-
proved^ are globally accepted as successful outcomes, and
were therefore used in this study to indicate a successful sur-
gical outcome.
Methodology for assessing the correlation between the two
instruments and generation of ICIQ-SF cut-off score
for success
We used two long-term follow-up datasets (3 and 8 years)
from a RCT (the E-TOT study; Table 1) performed between
April 2005 and April 2007 with follow-up until 2015 in a
tertiary urogynaecology centre in Scotland, UK [6, 7]. All
patients had urodynamic SUI or mixed UI (MUI, with pre-
dominant SUI) and were randomized to treatment with either
inside-out TVT-O (Ethicon Inc., Somerville, NJ) or Aris
outside-in TOT (Coloplast, Peterborough, UK) as a sole pro-
cedure. The datasets yielded 432 complete ICIQ-SF score/
PGI-I outcome data pairs. These datasets were from patients
who responded to follow-up postal questionnaire packs which
also included symptom severity, QoL and sexual function
questionnaires. We used the usual convention for the PGI-I
transition scale from 1 (very much better) to 7 (very much
worse). We determined the correlation between absolute
scores. We did not stratify the ICIQ-SF scores into mild, mod-
erate and severe, as this procedure has been shown to have
limited validity [9].
Methodology for the validation of the novel ISIC-SF
cut-off score for success
The correlations and cut-off scores generated were validated
on an independent dataset representing the 1-year and 4-year
follow-up from another multicentre RCT (the pilot SIMS
study; Table 1) for surgical management of SUI in women
[8] (Mostafa et al. Submitted for publication). Similar to the
E-TOT RCT, all patients had urodynamic SUI or MUI (with
predominant SUI) and were randomized to treatment with
either adjustable anchored SIMS (Ajust; C. R. Bard Inc., NJ)
or TVT-O, (Ethicon Inc., Somerville, NJ) as a sole procedure.
These patients were respondents to the same follow-up postal
questionnaire pack as in the E-TOTRCT. The datasets yielded
242 ICIQ-SF score/PGI-I outcome data pairs.
SPSS v. 22.0 (IBM Corp., Armonk, NY) was use for all
statistical analyses. One-way ANOVAwas used to determine
whether the mean posttreatment ICIQ-SF scores were signif-
icantly different between the different PGI-I categories to
eliminate confounders. Correlation analysis was then done
yielding Pearson coefficients. Receiver operator characteristic
(ROC) curves were generated for each cohort with ICIQ-SF
scores and PGI-I outcomes (success/failure) as variables using
the SPSS ROC function. These were used to generate sensi-
tivity and specificity cut-off values. Tukey type post-hoc anal-
ysis was performed.
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Results
ICIQ-SF cut-off score for success
The correlation between the ICIQ-SF score at follow-up and
PGI-I outcome was highly significant at the 0.01 level (two-
tailed; Pearson coefficient −0.629). Higher ICIQ-SF scores
correlated with a ‘poorer’ PGI-I score. The ROC analysis
and the analysis of the sensitivities and specificities in both
datasets gave an ICIQ-SF cut-off score of 6 as approximately
90 % sensitive and 85 % specific for success or failure as
judged by the PGI-I, This was deemed to be both clinically
and statistically sufficiently robust to proceed to the validation
stage (Table 2).
Validation of the generated ICIQ-SF cut-off score
As stated above, the correlation between the ICIQ-SF score at
follow-up and PGI-I outcome was significant at the 0.01 level
(two-tailed; Pearson coefficient: −0.630). The ROC curve
analysis evaluating the relationship between ICIQ-SF score
and PGI-I success/failure outcome gave an ICIQ-SF cut-off
score of 6 for use as a test for success in the validation cohort
and compared with actual outcomes. Cohen’s kappa coeffi-
cient for the correlation between the two datasets was 0.83 (95
% CI 0.74 – 0.89), clearly indicating the validity of the cut-off
score.
Discussion
Both PGI-I and ICIQ-SF are validated methods in postinterven-
tion assessment of UI. Despite being widely used in clinics and
research settings and the wealth of information about ICIQ-SF
and PGI-I separately, there has been a longstanding and ongo-
ing effort to robustly correlate these two valuable instruments
so that results from different authors/research groups can be
compared [1–5]. The PGI-I is a global index that is widely used
to rate the response of a condition to a therapy (transition scale).
It is a simple, direct, easy to use scale that is intuitively under-
standable by clinicians and patients [3]. The PGI-I has been
found to have excellent construct validity when compared with
various assessment variables: incontinence episode frequency,
the Incontinence Quality of Life Questionnaire, and the fixed
volume (400 mL) stress pad test [5]. Such global ratings can be
precise when used to assess the same person over time, but they
have a degree of imprecision across the spectrum of different
people in whom theymight be used [5]. PGI-I has recently been
found by Hossack and Woo to be a valid assessment tool even
following prostatectomy, and PGI-I is now being looked at with
great interest in urology research. It has shown excellent corre-
lation with the symptom score and QoL index in urology re-
search [17]. Most recently PGI-I was used in the Bladder
Ultrasound Study (BUS trial) funded by the Health
Technology Assessment Programme with a follow-up of up
to 20 months in women with overactive bladder [16].
The ICIQ-SF is a subjective measure of severity of urinary
loss and QoL for those with UI. This PROM tool takes 5 min
or less time to administer and no training, and hence is widely
used in both clinical and research settings. ICIQ-SF has been
tested and validated in men and women with primary SUI.
Cut-off scores for severity of UI in women have been reported
by Klovning et al. in a cohort of 1,812 women responding to a
general health questionnaire [9]. Score ranges were 1 – 5
(slight), 6 – 12 (moderate), 13 – 18 (severe) and 19 – 21 (very
severe).
ICIQ-SF has the ability to detect changes after both conser-
vative and surgical treatment. The minimal detectable change
(MDC) and minimally clinically important difference (MCID)
after intervention for UI are not yet established, but there has
been initial investigation in this area [5–10]. Sirls et al. assessed
597 women in the TOMUS RCT and found that the minimum
important difference (MID) for the ICIQ-SF in a population of
women with stress-predominant UI is −5 for assessment at
12 months and −4 for assessment at 24 months [10]. They
concluded that MID may be overestimated in surgical cohorts
because of uniformly high preoperative scores without signifi-
cant variability that show a large improvement after treatment
[10]. Nyström et al. also found that the changes in ICIQ-SF and
ICIQ-LUTS QoL scores in women with SUI after pelvic floor
muscle training reflected clinically relevant improvements [11].
They included 218 women with a 4-month follow-up. The
Table 1 Datasets
Dataset Study Follow-
up (years)
Number of
data pairs
Total
Correlation and generation
of cut-off score
E-TOT RCT 3 238 432
8 194
Validation SIMS RCT 1 131 242
4 111
Table 2 Consolidated specificities and sensitivities generated by ROC
analysis of ICIQ-SF scores at follow-up and success/failure on PGI-I
Dataset ICIQ-SF score Sensitivity 1 − specificity
Generation dataset 4.500 0.982 0.348
5.500 0.919 0.168
6.500 0.854 0.152
7.500 0.688 0.115
Validation dataset 4.500 0.778 0.060
5.500 0.823 0.120
6.500 0.889 0.158
7.500 0.903 0.328
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MID was defined as the mean change in score in women who
experienced a small improvement. Similar to our results,
Nyström et al. [11] found that PGI-I outcome correlated signif-
icantly with the ICIQ-SF score (r = 0.547, P < 0.0001) while
the MID was −2.52. The clear discrepancy between MCID in
the above studies shows that more research is needed in this
area. Nyström et al. hypothesized that PGI-I outcome may be
better correlated with postoperative ICIQ-SF score than the
change in the score over time which was clearly lower than
that found by Sirls et al. [10].
In our study, we analysed the results from two large
datasets representing the PROM up to 8 years following treat-
ment with a midurethral sling (MUS). In this RCTwhich was
started in 2005, a baseline ICIQ-SF score was not available. A
clear strong correlation between PGI-I outcome and ICIQ-SF
score was shown, and we identified a postoperative ICIQ-SF
score of 6 as a marker of successful outcome according to
PGI-I with reasonable specificity (85 %) and sensitivity
(90 %). The score was then validated in two datasets
representing follow-up periods of up to 4 years in a separate
RCT also assessing outcomes following treatment with a
MUS, but where the baseline ICIQ-SF scores were known.
This demonstrated that the results are fully validated for the
majority of women undergoing treatment with a MUS.
NICE (National Institute for Care and Health Excellence)
guidelines on UI (CG171) [12], a Cochrane review [13], and
most recently a SCENIHR (Scientific Committee on Emerging
and Newly Identified Health Risks) report all encourage authors
to undertake RCTs with long-term follow-up and to compare the
results with those of relatively old RCT.Many studies, like ours,
will not have had the chance to use the ICIQ-SF at baseline given
the timeline of trials and the publication of ICIQ-SF in 2004. Our
results showing the correlation between the ICIQ-SF score and
PGI-I outcome and the validity of the ICIQ-SF cut-off score
would enable the ICIQ-SF to be administered postoperatively
in these trials and enable their results to be compared with those
of other RCTs in a meta-analysis. This would allow the clinical
community to fill the gap in the evidence for the long-term
outcomes following surgical treatment of SUI. Unlike MCID,
our highlighted ICIQ-SF cut-off score was not affected by the
length of follow-up up to 8 years. In-addition, this novel validat-
ed ICIQ-SF cut-off score will be a valuable aid in counselling
patients during their follow-up after surgery for incontinence. A
postoperative ICIQ-SF score of ≤6 is likely to translate to a
patient-reported successful outcome according to the PGI-I.
Recently, Larsen et al. [14] compared the PGI-I and the
ICIQ-SF score in women undergoing surgery for UI or pelvic
organ prolapse and found that the PGI-I score correlates better
with the postoperative ICIQ score than the change in score
after surgery. They concluded that this may be due to patients’
recall bias, and warned that PGI-I tends to overestimate
patient-reported success compared with the change in ICIQ
score after treatment.
Methodology
In the accompanying editorial, Cartwright et al. [15]
questioned their methodology of converting the individual
scores for both questionnaires to the same scale as the numer-
ical values assigned to each category in the underlying items
are somewhat arbitrary [15]. The use of four large datasets
assessing different follow-up times after treatment with a
MUS (1, 3, 4 and 8 years) is a major strength of our study.
The fact that the cut-off score did not seem to be affected by
the length of follow-up or the type of MUS used is important
for both clinical and research use. A potential limitation is that
correlating two questionnaires that measure the same clinical
intervention may be inappropriate. Cartwright et al. [15] argue
that the differences between the PGI-I and the ICIQ reflect
true differences in what they measure. PGI-I provides a more
global overview of treatment success that is more likely to
fully encompass the range of benefits and harms of surgery
compared to a disease-specific questionnaire such as ICIQ.
Conclusions
This two-stage study provided a robust well-validated postop-
erative ICIQ-SF cut-off score (of 6/21) that is likely to trans-
late to a patient-reported successful outcome on PGI-I follow-
ing surgical treatment with a MUS in women at different
stages of follow-up from 1 to 8 years. Such a cut-off score
may enable comparison of results between various studies and
serve as a valuable guide for surgeons to counsel patients
before and/or after surgical treatment. Our study fills the re-
search gap in providing a way to compare trial results when
baseline ICIQ-SF scores are not available.
Compliance with ethical standard
Ethical consideration The ETOT and SIMS studies received all re-
quired approvals from the Research and Development Departments in
Glasgow University and Aberdeen University and the relevant ethics
committees, and were registered on www.clinicaltrials.gov
Financial disclosures Mohamed Abdel-fattah certifies that the con-
flicts of interest, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the
article (e.g. employment/affiliation, grants or funding, consultancies, hon-
oraria, stock ownership or options, expert testimony, royalties, or patents
filed, received, or pending), are the following:
All authors of this paper have received travel grants from different
pharmaceutical companies (Pfizer, Astellas, Lilly, Ethicon, Coloplast) to
attend medical conferences.
The University of Aberdeen received a research grant from Coloplast
in 2009.
Funding/Support and role of the sponsor The initial phase of this
study (up to 3 years follow-up) was funded by a grant from the Henry
Smith Charity (Address: 6th Floor, 65 Leadenhall Street, London, EC3A
2AD; registered charity number 230102). Dr. Karmakar was funded by an
IUGA Clinical Fellowship Grant 2014.
98 Int Urogynecol J (2017) 28:95–100
Appendix 1
Int Urogynecol J (2017) 28:95–100 99
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Hilton P, Robinson D (2011) Defining cure. Neurourol Urodyn
30(5):741–745
2. Staskin D, Kelleher C, Avery K (2009) Initial assessment of urinary
and faecal incontinence in adult male and female patients. In:
Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence. 4th
International Consultation on Incontinence, Paris July 5–8, 2008,
4th edn. Health Publication Ltd, Paris, pp 332–412
3. Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M,
Symptom Quality of Life Assessment Committee of the First
International Consultation on Incontinence (2002) Quality of life
assessment in men and women with urinary incontinence. J Urol
168(3):896–905
4. Donovan JL, Badia X, Corcos J (2002) Symptom and quality of life
assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds)
Incontinence, 2nd edn. Health Publication Ltd, Plymouth, pp
270–316
5. Karantanis E, FynesM,Moore KH, Stanton SL (2004) Comparison
of the ICIQ-SF and 24-hour pad test with other measures for eval-
uating the severity of urodynamic stress incontinence. Int
Urogynecol J Pelvic Floor Dysfunct 15(2):111–116
6. Abdel-FattahM,Mostafa A, Familusi A, Ramsay I, N’dow J (2012)
Prospective randomised controlled trial of transobturator tapes in
management of urodynamic stress incontinence in women: 3-year
outcomes from the evaluation of transobturator tapes study. Eur
Urol 62(5):843–851
7. Karmakar D, Mostafa A, Abdel-Fattah M (2015) Long-term out-
comes (8-years) from the prospective randomized control trial of
trans-obturator tapes for stress incontinence in women (the ETOT
study). Int Urogynecol J 26(1 suppl):S74–S75
8. Mostafa A, Agur W, Abdel-All M, Guerrero K, Lim C, Allam M,
Yousef M, N’Dow J, Abdel-Fattah M (2013) Multicenter
prospective randomized study of single-incision mini-sling vs
tension-free vaginal tape-obturator in management of female stress
urinary incontinence: a minimum of 1-year follow-up. Urology
82(3):552–559
9. Klovning A, Avery K, Sandvik H, Hunskaar S (2009) Comparison
of two questionnaires for assessing the severity of urinary inconti-
nence: The ICIQ-UI SF versus the incontinence severity index.
Neurourol Urodyn 28(5):411–415
10. Sirls LT, Tennstedt S, Brubaker L, Kim HY, Nygaard I, Rahn DD,
Shepherd J, Richter HE (2015) The minimum important difference
for the International Consultation on Incontinence Questionnaire-
Urinary Incontinence Short Form in women with stress urinary
incontinence. Neurourol Urodyn 34(2):183–187
11. Nyström E, Sjöström M, Stenlund H, Samuelsson E (2015) ICIQ
symptom and quality of life instruments measure clinically relevant
improvements in women with stress urinary incontinence.
Neurourol Urodyn 34(8):747–751
12. National Institute for Care and Health Excellence (2013) Urinary
incontinence in women: management. NICE guidelines CG171.
https://www.nice.org.uk/guidance/cg171
13. Ford AA, Rogerson L, Cody JD, Ogah J (2015) Mid-urethral sling
operations for stress urinary incontinence in women. Cochrane
Database Syst Rev 7:CD006375
14. Larsen MD, Lose G, Guldberg R, Gradel KO (2016) Discrepancies
between patient-reported outcomemeasures when assessing urinary
incontinence or pelvic- prolapse surgery. Int Urogynecol J 27(4):
537–543. doi:10.1007/s00192-015-2840-4
15. Cartwright R, Brown H, Rizk D (2016) Patient reported outcome
measures after incontinence and prolapse surgery: are the pictures
painted by the ICIQ and PGI-I accurate? Int Urogynecol J 27(4):
507–508. doi:10.1007/s00192-015-2929-9
16. Health Technology Assessment Programme (2016) HTA - 09/22/
122: Bladder ultrasonography for diagnosing detrusor overactivity:
test accuracy study and economic evaluation. http://www.nets.nihr.
ac.uk/projects/hta/0922122
17. Hossack T, Woo H (2014) Validation of a patient reported outcome
questionnaire for assessing success of endoscopic prostatectomy.
Prostate Int 2(4):182–187
18. Cartwright R, Srikrishna S, Cardozo L, Robinson D (2011) Patient-
selected goals in overactive bladder: a placebo controlled random-
ized double-blind trial of transdermal oxybutynin for the treatment
of urgency and urge incontinence. BJU Int 107(1):70–76
100 Int Urogynecol J (2017) 28:95–100
